However, some features of CD133-positive cells contrast with the CSC concept, e.g., CD133-overexpressing tumour cells showed higher levels of telomerase and higher proliferative activity [30]; lower CD133 expression was observed after neoadjuvant chemoradiotherapy of pancreatic cancer [31]. This evidence concerns the gene PROM1 and pancreatic neoplasm.